Literature DB >> 14645912

Induction of an antigen-specific immune response and partial protection of cattle against challenge infection with foot-and-mouth disease virus (FMDV) after lipopeptide vaccination with FMDV-specific B-cell epitopes.

Bettina-Judith Höhlich1, Karl-Heinz Wiesmüller2, Bernd Haas1, Wilhelm Gerner1, Roberto Correa3, Hans-Robert Hehnen3, Tobias Schlapp3, Eberhard Pfaff1, Armin Saalmüller1.   

Abstract

To evaluate the potential of chemically synthesized lipopeptides for vaccination against foot-and-mouth disease (FMD), seven lipopeptides containing the immunostimulating principle of bacterial lipoproteins and linear B-cell epitopes of FMDV strain O(1)Kaufbeuren (O(1)K) were used to immunize cattle (n=7). Animals were vaccinated once and 21 days after immunization animals were infected with the homologous virus. Four animals were protected. After vaccination, as well as after challenge infection, B- and T-cell responses were examined. Sera were tested for virus- and peptide-specific antibodies and showed after vaccination only a weak antibody response. After challenge infection, an increase in antibody titre was obvious but there was no correlation between antibody titre and protection. The reactivity of the cellular immune system was detected by analyses of PBMCs for virus- and peptide-specific T-lymphocytes. With regard to the virus-specific T-lymphocytes, a heterogeneous reactivity could be shown. No correlation between virus-specific T-cell proliferation and protection was found. Obvious was the fact that all protected animals showed after vaccination a strong T-cell response against at least one of the peptides used for immunization. These results suggest a correlation between the onset of an antigen-specific T-cell reaction and protection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645912     DOI: 10.1099/vir.0.19366-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Foot-and-mouth disease virus exhibits an altered tropism in the presence of specific immunoglobulins, enabling productive infection and killing of dendritic cells.

Authors:  L Robinson; M Windsor; K McLaughlin; J Hope; T Jackson; B Charleston
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

2.  Treatment of autoimmune diabetes in NOD mice by Toll-like receptor 2 tolerance in conjunction with dipeptidyl peptidase 4 inhibition.

Authors:  D-H Kim; J-C Lee; M-K Lee; K-W Kim; M-S Lee
Journal:  Diabetologia       Date:  2012-09-27       Impact factor: 10.122

3.  Construction and immune response characterization of a recombinant pseudorabies virus co-expressing capsid precursor protein (P1) and a multiepitope peptide of foot-and-mouth disease virus in swine.

Authors:  Yannan He; Ping Qian; Keshan Zhang; Qingxia Yao; Dang Wang; Zhuofei Xu; Bin Wu; Meilin Jin; Shaobo Xiao; Huanchun Chen
Journal:  Virus Genes       Date:  2008-02-02       Impact factor: 2.332

4.  A pseudotype baculovirus expressing the capsid protein of foot-and-mouth disease virus and a T-cell immunogen shows enhanced immunogenicity in mice.

Authors:  Yimei Cao; Zengjun Lu; Pu Sun; Yuanfang Fu; Feipeng Tian; Xiaofang Hao; Huifang Bao; Xiangtao Liu; Zaixin Liu
Journal:  Virol J       Date:  2011-02-23       Impact factor: 4.099

5.  Supplementation of dietary germanium biotite enhances induction of the immune responses by foot-and-mouth disease vaccine in cattle.

Authors:  Myunghwan Jung; Min-Kyoung Shin; Seung-Bin Cha; Seung Won Shin; Anna Yoo; Won-Jung Lee; Hong-Tae Park; Jong-Hyeon Park; Byounghan Kim; Yeon-Kwon Jung; Han Sang Yoo
Journal:  BMC Vet Res       Date:  2014-08-12       Impact factor: 2.741

6.  Antigenic heterogeneity of capsid protein VP1 in foot-and-mouth disease virus (FMDV) serotype Asia 1.

Authors:  S M Sabbir Alam; Ruhul Amin; Mohammed Ziaur Rahman; M Anwar Hossain; Munawar Sultana
Journal:  Adv Appl Bioinform Chem       Date:  2013-08-13

Review 7.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.